First patient dosed using oral PROTAC in development for neurodegenerative diseases 20-Feb-2024 By Liza Laws A clinical-stage biotechnology company creating a new class of drugs today (Feb 20) announced that a first subject has been dosed in a phase 1 clinical trial.